Kurzfassung

A randomized phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and
anthracycLine-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia